Microbot Medical begins commercial sales with $105K Q1 revenue after FDA clearance

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

Key Changes

• high

  Company generated first commercial revenues of $105,000 in Q1 2026 from LIBERTY® Endovascular Robotic System sales following September 2025 FDA clearance and November 2025 limited market release, marking transition from pre-revenue development stage to commercial operations.

  MD&A: Revenue Recognition verify on EDGAR →
• high

  Working capital strengthened to $73.1 million at March 31, 2026 from $28.8 million year-ago, reflecting $62.8 million in capital raised during fiscal 2025 to fund commercial launch and operations.

  MD&A: Liquidity verify on EDGAR →
• high

  Emory University Hospital adopted LIBERTY® system for patient care and is collaborating to establish an Endovascular Robotics Program, providing institutional validation and platform for physician training.

  MD&A: Commercial Milestones verify on EDGAR →